© EPA

Bayer’s annual report states that the main parameters used to manage the group “are the cash value added and cash flow return on investment”. In the documents relating to its $122/share bid for Monsanto, shareholders are instead promised accretion in earnings per share and a likely upward re-rating. Alarm bells are ringing; its shares are down 14 per cent in just over a week.

The German group is offering a $14bn premium over Monsanto’s undisturbed equity value, all in cash. It expects cost savings of $1.5bn a year within three years. Taxed and capitalised, they are worth perhaps $10bn. If Monsanto forces a higher offer, that gap will widen; at $125 a share, the shortfall approaches $6bn.

Bayer has historically struggled to generate returns on invested capital that exceed the cost of that capital. Managers have promised this deal will do so within three years. Shareholders, facing a cash call of over €13bn ($14.5bn), are right to be concerned.

Email the Lex team at lex@ft.com

Get alerts on Bayer AG when a new story is published

Copyright The Financial Times Limited 2019. All rights reserved.

Follow the topics in this article